Drug Action
Erenumab is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor, inhibiting the function of CGRP, and thereby preventing migraine attacks.
PDF page 520
Loading InternPractice…
Drug reference
Erenumab is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor, inhibiting the function of CGRP, and thereby preventing migraine attacks.
PDF page 520
Prophylaxis of migraine (in patients who have at least 4 migraine days per month) (initiated by a specialist) ▶BY SUBCUTANEOUS INJECTION ▶Adult: 70 mg every 4 weeks; increased if necessary to 140 mg every 4 weeks, consider discontinuing if no response after 3 months of treatment
PDF page 520
Erenumab is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1; manufacturer advises to record the brand name and batch number after each administration. l HANDLING AND STORAGE Manufacturer advises store in a refrigerator (2-8°C) and protect from light—consult product literature for further information regarding storage outside refrigerator.
PDF page 520
Scottish Medicines Consortium (SMC) decisions SMC No. SMC2134 The Scottish Medicines Consortium has advised (April 2019) that erenumab (Aimovig ®) is accepted for restricted use within NHS Scotland for the prophylaxis of migraine in adults who have at least four migraine days per month and in whom at least three prior prophylactic treatments have failed. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
PDF page 520
▶Common or very common Constipation. muscle spasms. skin reactions ▶Frequency not known Oedema. swelling
PDF page 520
Manufacturer advises avoid—limited information available.
PDF page 520
Manufacturer advises avoid during first few days after birth—possible risk from transfer of antibodies to infant. After this time, use during breast- feeding only if clinically needed.
PDF page 520
Manufacturer advises injection into the abdomen, thigh, or upper arm (if not self-administered). Patients may self-administer Aimovig ® after appropriate training in subcutaneous injection technique.
PDF page 520
There can be variation in the licensing of different medicines containing the same drug. Solution for injection EXCIPIENTS: May contain Polysorbates, sucrose ▶Aimovig (Novartis Pharmaceuticals UK Ltd) A Erenumab 70 mg per 1 ml Aimovig 70mg/1ml solution for injection pre-filled pens | 1 pre-filled disposable injection P £386.50 Erenumab 140 mg per 1 ml Aimovig 140mg/1ml solution for injection pre-filled pens | 1 pre-filled disposable injection P £386.50 (Hospital only)
PDF page 521
Self-administration Manufacturer advises that patients and their carers should be given training in subcutaneous injection technique if appropriate.
PDF page 520
70 mg every 4 weeks; increased if necessary to
First-line fragment. Read the complete Indications and Dose section above.
PDF page 520